Document Detail

Synergistic effect of released aspirin/heparin for preventing bovine pericardial calcification.
MedLine Citation:
PMID:  10718766     Owner:  NLM     Status:  MEDLINE    
Calcification is a frequent cause of the clinical failure of bioprosthetic heart valves fabricated from glutaraldehyde pretreated bovine pericardium (GATBP). Aspirin, a potent antiplatelet drug, and heparin, an anticoagulant, are commonly used for postimplant complications such as thrombosis and thromboembolism. Aspirin and heparin were embedded in chitosan/polyethylene vinylacetate co-matrix to develop a prolonged release form. The effect of these drugs towards the bioprosthetic calcification was investigated by in vitro and in vivo models. In vitro and in vivo evaluation suggest that the released aspirin/heparin from the co-matrix had a synergistic effect in inhibiting GATBP calcification. In vivo subcutaneous co-implantation was performed with PEG-20,000 grafted bovine pericardium (PEG-GABP), aspirin, and heparin. Biochemical, histological, and scanning electron microscopic evaluation of retrieved samples demonstrated a significant reduction in calcium deposition and alkaline phosphatase activity on PEG-GABP compared to GATBP. It seems that the aspirin/heparin combination synergistically inhibits the pericardial calcification in addition to their antithrombotic function.
S C Vasudev; T Chandy; C P Sharma; M Mohanty; P R Umasankar
Related Documents :
9549926 - Treatment of polycythemia vera.
23799576 - Differential effects of paclitaxel and docetaxel on gap junctions affects their cytotox...
24519486 - Dual responsive supramolecular nanogels for intracellular drug delivery.
24255856 - P31(comet) inactivates the chemically induced mad2-dependent spindle assembly checkpoin...
16400516 - Methods to assess in vitro drug release from injectable polymeric particulate systems.
7947416 - Drug abuse in schizophrenia: comparison of patients who began drug abuse before their f...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Artificial organs     Volume:  24     ISSN:  0160-564X     ISO Abbreviation:  Artif Organs     Publication Date:  2000 Feb 
Date Detail:
Created Date:  2000-04-04     Completed Date:  2000-04-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7802778     Medline TA:  Artif Organs     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  129-36     Citation Subset:  IM    
Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Poojappura, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alkaline Phosphatase / analysis
Anticoagulants / administration & dosage,  therapeutic use*
Aspirin / administration & dosage,  therapeutic use*
Calcinosis / prevention & control*
Calcium / analysis
Chitin / analogs & derivatives
Delayed-Action Preparations
Drug Delivery Systems
Drug Synergism
Heart Valve Prosthesis*
Heparin / administration & dosage,  therapeutic use*
Microscopy, Electron, Scanning
Pericardium* / chemistry,  ultrastructure
Platelet Aggregation Inhibitors / administration & dosage,  therapeutic use*
Polyethylene Glycols
Prosthesis Failure
Rats, Wistar
Surface-Active Agents
Reg. No./Substance:
0/Anticoagulants; 0/Biopolymers; 0/Delayed-Action Preparations; 0/Platelet Aggregation Inhibitors; 0/Polyethylene Glycols; 0/Polyvinyls; 0/Surface-Active Agents; 1398-61-4/Chitin; 24937-78-8/ethylenevinylacetate copolymer; 50-78-2/Aspirin; 7440-70-2/Calcium; 9005-49-6/Heparin; 9012-76-4/Chitosan; EC Phosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparative In vitro evaluation of two different preparations of small diameter polyurethane vascula...
Next Document:  Biodesign of a skeletal muscle flap as a model for cardiac assistance.